Updated cholesterol guidelines: what’s different and the key steps to avoid heart disease

How cholesterol management has changed

The update moves towards tighter cholesterol targets based on each person’s risk. The main change concerns low-density lipoprotein (LDL) goals, with lower targets recommended depending on assessed risk.

• Those at borderline or intermediate risk should keep LDL below 2.6 mmol/L.
• High-risk individuals are advised to aim under 1.8 mmol/L, and people with a previous cardiovascular event (classed as very high risk) should target less than 1.4 mmol/L.
• Any LDL over 4.9 mmol/L is flagged for immediate drug treatment.

A new tool, the PREVENT-ASCVD calculator, is central to these guidelines. It estimates the 10-year risk of a cardiovascular event and sorts people into four categories, low, borderline, intermediate and high, so treatment can be tailored. Roger Blumenthal, chair of the writing committee, points out that it can recalculate risk using data usually collected during annual check-ups.

What the evidence says

The guidelines are grounded in scientific evidence showing that raised LDL is a major contributor to heart attacks and strokes. Many studies show that cutting LDL reduces deaths from cardiovascular disease. As Juan Pablo Costabel, a cardiologist, puts it: “the lower the LDL, the lower the risk of events such as myocardial infarction or stroke”.

Lowering LDL to physiological ranges does not harm hormone or brain function; evidence indicates it may help prevent cognitive decline and brain damage linked to microinfarctions (small, often silent areas of brain injury). This is consistent with the association between vascular health and cholesterol levels.

Drugs and lifestyle: what to do and when

The guidelines don’t just focus on cholesterol numbers; they recommend decisions based on a full cardiovascular risk assessment. They list specific situations where statin therapy is clearly advised:

• patients with a history of myocardial infarction,
• stroke,
• subclinical atherosclerosis,
• LDL above 4.9 mmol/L, or
• diabetes.

Statins remain a mainstay of treatment, noted for their safety and the large body of research showing they cut major cardiovascular events.

Pablo Corral, a specialist in internal medicine, stresses the need for clinicians and patients to make shared decisions, weighing both the benefits and possible side effects of drug treatments.

Lifestyle measures remain the bedrock of prevention, alongside any medication. Recommendations include adopting a healthy diet, keeping to a healthy weight, doing regular physical activity, avoiding tobacco, prioritising good sleep, and managing stress. There is agreement that in low-risk patients, lifestyle changes may be enough without starting medication.

Why cardiovascular disease is still a global problem

Despite progress, cardiovascular disease is still the leading cause of death worldwide. Contributing factors include an ageing population, missed guideline targets, and the rising prevalence of risk factors such as sedentary lifestyles, obesity, stress and diabetes. According to Pablo Corral, the main hurdle is getting people to stick with the lifestyle changes needed to reach the set goals and reduce the disease burden.

The new ACC/AHA guidelines are a tool to help separate high-risk from very high-risk patients and offer tailored interventions. By following these recommendations and promoting healthier habits, clinicians and patients may reduce the rate of cardiovascular disease and protect quality of life.